Partner Details


Oxford Biomaterials (United Kingdom)


http://www.oxfordbiomaterials.com

Oxford Biomaterials is a medical devices company founded in 2001 to develop Spidrex: a novel silk-based absorbable biomaterial for use in the repair and regeneration of human tissues.

Our unique technology has wide-ranging market appeal and is being taken up in four separate ventures including cartilage, suturing, and nerve repair products.

For the past two years, efforts have focussed on the development of our Spidrex Bone Graft Material: SilkBone™ - the world’s first absorbable, load bearing, off-the-shelf Bone Graft Material.

Our unique absorbable product combines mechanical support comparable to real bone, with a highly porous and hydrophilic structure such that patient’s own regenerating bone will eventually replace the implant.


Progentix (Netherlands


http://www.progentix.com

Progentix BV, founded in 2004, is a Dutch life sciences company that develops an innovative platform technology based on an automated, closed bioreactor system to expand bone marrow derived adult mesenchymal stem cells.

This expansion system is stand-alone, simple-to-operate and does not require a complex laboratory environment. It can be placed within any hospital department, and is able to generate over 200 million expanded adult stem cells.

Adult stem cells can be used in regenerative medicine to treat various tissue disorders (such as bone and cartilage defects, cardiovascular disease and central neural system disorders) and as a screening platform for the discovery of new drugs, small molecules and genes.

Progentix focuses on the clinical use of adult stem cells for bone regeneration and for that reason also develops a unique range of synthetic osteoinductive biomaterial scaffolds.

SLU (Sweden)

http://www.vhfak.slu.se/ 

SLU is a sector University working side by side with the larger Uppsala University. It employs 2500 staff of whom 1000 are academic. Its research is focussed on the four areas linked to agriculture - Veterinary Medicine, Agriculture, Forestry and Horticulture. It has aimed at an international frontline position in modern molecular biology, microbiology and protein chemistry including advanced structural biological techniques including x-ray crystallography, NMR and 3-D molecular modelling. Expertise available at SLU in the field of orthopaedics medicine and in vivo trials, combined with a leading molecular-based science program makes SLU an attractive partner in this proposal.

Soton (United Kingdom)

http://www.som.soton.ac.uk/divisions/FOAD/ortho/ 

Professor Richard Oreffo and Dr Helmtrud Roach are part of the Bone and Joint Research Group based within the RAE 5* rated Division of Foetal Origins of Adult Disease (FOAD) directed by Professor Hanson and Professor Barker FRS. The group will shortly become part of the new Centre of Developmental Origins of Health and Disease. The new building is located on the Southampton General Hospital site and comprises three stories with an additional sub-basement and will provide ~2,600 m² accommodation to house 80 researchers and support staff. Within the major laboratory complexes will be a dedicated Human Stem Cell and Developmental Biology Unit and centrally-managed generic facilities for Molecular Biology; Vascular Biology; Endocrine and Metabolite Analysis; Tissue Preparation, Microscopy and Image Analysis. The new DOHAD Centre building has been funded by a £4.5M from the university’s SRIF allocation with funds from Wolfson Foundation and Weston Foundation (£5.5M). The centre will bring together a range of staff groups with multidisciplinary expertise in programming mechanisms associated with embryos and stem cell; cardiovascular and vascular biology; metabolism and endocrinology; and mesenchyme and bone development. University Orthopaedics is also associated with a large clinical facility for Trauma and Orthopaedics within Southampton University Hospital NHS Trust. This wealth of equipment, and the know how of the lead applicants in the field of bone tissue engineering is the reason Soton have been invited to join the consortium.

UNIVBRIS (United Kingdom)

http://www.chm.bris.ac.uk/inorg/mann/webpage.htm 

Professor Steve Mann FRS has established an international reputation for work in self-assembly/templating approaches in materials chemistry. His research is principally concerned with the chemical synthesis and characterization of complex forms of organized matter, particularly at the bioinorganic interface. Specifically, his work has explored the interface between biomineralization and materials chemistry, from which he has developed a conceptual framework for the synthetic construction of higher-order inorganic structures. His work on biomineralization has pursued a chemical and structural approach to the study of small-scale functional structures, with particular focus on the synthesis and assembly of nanoscale magnets in magnetotactic bacteria, superparamagnetic iron oxides in ferritin protein cages, and complex chiral architectures in the calcium carbonate coccoliths of certain marine algae. In parallel, he has pioneered a biomimetic approach to materials chemistry based on the use of self-assembled organic structures for the synergistic synthesis of organized inorganic matter. Prof Mann has published over 300 scientific papers, many of which are in highly prestigious journals including Science and Nature. The widespread importance of his work has been recognised in setting up the Centre for Organized Matter Chemistry of which he is the Director in the School of Chemistry at UNIVBRIS. The Centre's research activities are housed in new laboratories and associated with the Electron Microscopy Facility, which consists of five electron microscopes all with EDX analysis systems, and are currently housed in a newly refurbished site with associated laboratory and office space. The Facility is supported by a full-time electron microscopy research associate and technician. Full training is provided on the operation of all the microscopes and associated equipment. Basic specimen preparation facilities for routine electron microscopy are also available. Besides the EM facilities, the Centre has full use of a wide range of facilities required in materials research, including; XRD, TGA, FTIR, UV/VIS and liquid and solid state NMR spectroscopies, BET, SAXS, zeta potential analysis, MS, GPC and high temperature furnaces. In terms of general research and academic infrastructure, the School of Chemistry at UNIVBRIS is a grade 5* department with 47 members of staff, and a research community of over 200 postgraduate research students and postdoctoral research assistants offering training in a wide variety of distinguished research programmes. Achieving correct mineralisation of composites is of paramount importance to the project’s likelihood of success which is why UNIVBRIS were invited to join the consortium.

UOXF.AT (United Kingdom)

http://users.ox.ac.uk/~abrg/ABRGweb.html 

UOXF.AT is one of the world´s oldest universities with an excellent record in almost every subject area. Over the last 100 years the university has world lead the world in the fields of zoology, ecology and developmental biology. UOXF.AT also offers excellent facilities with respect to studies of protein structure and function and has hosted leading protein scientists such as Dame Dorothy Hodgkin and Sir David Phillips. Prof Vollrath's group in UOXF.AT is one of the leading research laboratories worldwide working on silks and specifically spider silks. This has been been recognised by the recent award of a E.U. Training and Mobility grant to his group, which at this moment consists of 2 Dphil students and 4 senior scientists. Over the last 10 years the group has produced over 100 scientific publications on silk and attracted research funding from a wide range of sponsors and organisations. The focus of the research in the group has shifted over the years generating unique insights into all aspects of silk: from the chemistry of the spinning feedstocks to the physical details of the spinning conditions, from analysis of the mechanical properties to the underlying molecular mechanisms, from the descriptions of silk mechanics to highly accurate models and simulations. The analytical tools used by the group range from all levels of microscopy, from FTIR- and Raman-spectroscopy as well as X-ray diffraction on single sub-micron fibres to Nuclear Magnetic Resonance on both feedstock and fibres. In addition the group has several unique stress-strain testers as well as a dedicated Instron and a micro-rheometer. The insights of the group and the tools available will range from crucial to very useful when testing the different materials that the consortium aims to generate. Prof Vollrath’s unrivalled knowledge of arthropod silks and their mechanical properties is the central reason for UOXF.AT’s partnership.

3H Biomedical AB (Sweden)

http://www.3hbiomedical.com 

3H Biomedical AB is an innovative life-science company that develops market-driven products and testing for cell research, the cell-based tissue engineering market and therapeutic vaccine market. 3H Biomedical AB began to operate in April 2004. Dr. Mallen Huang and Dr. Anders Gobl are the founders of the company. 3H Biomedical have extensive expertise in the areas of cell and tissue culture, including: Stem cells, EPCs, Mesenchymal stem cells, Immune cells, Primary cell culture, Cell transplantation, Gene-modification of primary cells, Immunology, and Molecular Biology, as well as the formulation of therapeutic vaccines for the treatment and prevention of cancer and other diseases. 3H biomedical also has access to Hyaluronic Gel Technology.

Steinbeis Technology Transfer Centre for In Vitro Pharmacology and Toxicology (U Kon InPuT - Germany)


U Kon InPuT at the University of Konstanz, is an organisational unit of Steinbeis GmbH founded by the Federal State of Baden-Württemberg, Germany. U Kon InPuT develops, adapts, employs and validates a spectrum of meaningful in vitro and ex vivo test systems of animal and human origin. Since U Kon InPuT was founded in 1995 it has conducted more than 90 contracts with companies in eight countries. U Kon InPuT co-ordinated a validation study within the EU 5th Framework Programme, participated in two more FP5 shared cost actions and has carried out several direct contracts with the European Centre for the Validation of Alternative Methods (ECVAM) at the Joint Research Centre in Ispra, Italy. U Kon InPuT is part of an integrated project in FP6.

The group focuses on in vitro alternatives to animal experiments. Models are developed or taken over from academic research. After standardisation and optimisation, an evaluation and (pre-)validation is carried out. For this purpose, U Kon InPuT organises and participates in collaborative studies. U Kon InPuT will be responsible for assessment of in vitro immunological effects and biocompatibility testing as well as quality control issues as the leader of WP 6. U Kon InPuT will interact and give feedback to all other preclinical workpackages, aiming to optimize the developed materials to minimize the need for animal experiments. All of the technology and expertise required for its tasks are well established. U Kon InPuT will benefit from the proposed project by further expanding its applications of the In vitro Pyrogen Test in the field of biomaterial testing.

The team leader, Dr. Sonja von Aulock, is building up her own subgroup and currently ha 3 Ph. D. students, a post-doc and two diploma students within the subgroup of Prof. Thomas Hartung who will also take a lead role in the project. She is involved in the Graduate School ‘Biomedical Drug Research’, holds lectures in the cycles ‘Human Biology’ and ‘Biomedicine’, and is the scientific leader of the Marie Curie Research Training Network Pulmo-Net. As a representative of U Kon InPuT, she is involved in the management of the FP5 project ‘Spiderman’. Thomas Hartung, (M.D.Ph.D.) obtained his PhD in pharmacology (University of Konstanz) on an inflammatory liver cell model, and is an MD in Toxicology (University of Tübingen) on metabolism of xenobiotics. He has developed two in vitro alternatives to animal experiments which are currently being validated in co-operation with industry and national authorities. He has been awarded three prizes for research on replacing animal experiments (German Ministry of Health 1993, F.I.S.E.A. Luxembourg 1993, Doerenkamp-Zbinden Award 1996) and one in pharmacology (Sandoz 1995).